Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial
Authors' conclusion
We identified four clinically distinct T2D phenotypes with differential CV risks. Canagliflozin reduced the risk of CV events, irrespective of the phenotype, emphasizing its broad therapeutic acceptability.
Study context
- Population
- Individuals with T2D in the CANVAS Program and CREDENCE trial4 phenotypes
- Participants
- 966 / 4,169 / 7,108 / 2,300
- Comparison
- Canagliflozin across T2D phenotypes
- Phenotype 1n = 966
- Phenotype 2n = 4,169
- Phenotype 3n = 7,108
- Phenotype 4n = 2,300
- Primary endpoint
- Co-primary: hospitalization for HF (HHF) and composite of CV death or HHF
Methodological detailspooled latent class analysis, Cox proportional hazards models
- Pooled latent class analysis
- Cox proportional hazards models
Primary result
As reported in the abstract
HHF and CV death or HHF by phenotype
Hierarchical increase in primary endpoint risk across phenotypes; highest for Phenotype 4 (HR for hospitalization for heart failure (HHF))
7.57
95% CI 4.19–13.69
Original publication
Cardiovascular phenotypes in type 2 diabetes: Latent class analysis of the CANVAS Program and CREDENCE trial. Diabetes Obes Metab. Published 20 September 2024. doi:10.
Composed by AI from the published abstract and checked against it. How Briefs are made →